Nuvalent, Inc. (NUVL)

Market Cap	4.51B
Revenue (ttm)	n/a
Net Income (ttm)	-126.22M
Shares Out	64.07M
EPS (ttm)	-2.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	331,890
Open	73.48
Previous Close	72.49
Day's Range	70.13 - 74.79
52-Week Range	37.13 - 89.39
Beta	1.30
Analysts	Strong Buy
Price Target	84.67 (+20.36%)
Earnings Date	May 13, 2024

About NUVL

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Ph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 29, 2021
• Employees: 92
• Stock Exchange: NASDAQ
• Ticker Symbol: NUVL

Analyst Forecast

According to 10 analysts, the average rating for NUVL stock is "Strong Buy." The 12-month stock price forecast is $84.67, which is an increase of 20.36% from the latest price.

Price Target

$84.67

(20.36% upside)

Analyst Consensus: Strong Buy